AQUESTIVE THERAPEUTICS INC

NASDAQ: AQST (Aquestive Therapeutics, Inc.)

Last update: yesterday, 1:15AM

3.46

-0.25 (-6.61%)

Previous Close 3.71
Volume 3,360,585
Avg. Volume (3M) 2,388,779
Market Cap 434,879,456
Price / Sales 9.58
52 Weeks Range
2.93 (-15%) — 6.74 (94%)
Earnings Date 3 Nov 2026
Profit Margin -162.33%
Operating Margin (TTM) -114.13%
Diluted EPS (TTM) -0.650
Quarterly Revenue Growth (YOY) -41.00%
Current Ratio (MRQ) 6.12
Operating Cash Flow (TTM) -39.76 M
Levered Free Cash Flow (TTM) -22.57 M
Return on Assets (TTM) -24.63%

AIStockmoo Score

-1.7
Weak profitability. Ample short-term liquidity. Negative cash flow. info
From our AI Insight report's view of expected return against risk. info NA
Relative Valuation info NA
Implied Growth info NA
Valuation History info NA
Return on Capital info NA
Holdings' Value info NA
Risk Premium info NA
Market Valuation info NA
Downtrend over the past year. Far below its 52-week high. info
In a downtrend: the price is below its moving averages, and they are falling. It is close to them. Volume is heavier on down days. info
From our AI technical analysis of the chart. info NA
Candle Patterns info NA
No recent price targets, so based on how targets have been revised. info
Recent news mixed or neutral. info
Holdings' Sentiment info NA
Insiders net buying recently. Price is below what insiders paid. info
Institutions net +3.33% of shares in their latest 13F filings: 95 holders increased, 78 decreased (quarter to 30 Sep 2026). info
Short interest +15.1% from 31 Aug to 30 Oct 2026, 13.2 days to cover (FINRA). info
Market environment cautious. info
Sector outperforming the market.
The pillars agree, so the score is strengthened.
Earnings per share have gone up and down. Made a loss in recent years. info
Below its medium-term trend line. info
Price is low against its 52-week average. Down over 5 years. info
Trend down on all three terms. Short-term momentum falling. info
Price is near support. Levels trending down. info
Final Score -1.70
Show all

Market Trend

Short Term Medium Term
Industry Drug Manufacturers - Specialty & Generic (US) Mixed Mixed
Drug Manufacturers - Specialty & Generic (Global) Mixed Mixed
Stock Aquestive Therapeutics, Inc. Mixed Bullish

Similar Stocks

Stock Market Cap DY P/E (TTM) P/B Score
AQST 435 M - - - -1.7
SUPN 6 B 27.84% - 1.59 -1.0
ANIP 2 B - 13.74 2.57 -0.1
COLL 783 M - 23.13 2.72 0.1
TKNO 480 M - - - 0.8
TLRY 279 M - - 0.200 -2.2

Select this tab to load the latest available analysis.

Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.

Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
Investment Style Small Value
% Held by Insiders 10.78%
% Held by Institutions 61.11%

Ownership

Name Date Shares Held
Bratton Capital Management, L.P. 30 Sep 2026 9,810,958
Rosalind Advisors, Inc. 30 Sep 2026 2,000,000
Blue Owl Capital Holdings Lp 30 Sep 2026 1,390,632
Name Avg. Buy ($) Avg. Sell ($) Net Quantity Net Value ($)
DALY RICHARD J 3.52 - 28,025 98,648
DAVIS MATTHEW W. - 3.55 -12,500 -44,360
Aggregate Net Quantity 15,525
Aggregate Net Value ($) 54,288
Aggregate Avg. Buy ($) 3.52
Aggregate Avg. Sell ($) 3.55
Insider Range ($)
3.52 (1%) — 3.57 (3%)
Name Holder Date Type Quantity Price Value ($)
DAVIS MATTHEW W. Officer 12 Nov 2026 Sell (-) 7,197 3.57 25,693
DAVIS MATTHEW W. Officer 10 Nov 2026 Disposed (-) 5,303 3.52 18,667
DALY RICHARD J Director 10 Nov 2026 Buy (+) 28,025 3.52 98,648

Institutions

Institutional ownership: 65.06%

Positions Holders Shares
Increased 95 11,250,763
Decreased 78 7,172,973
New 26 2,010,558
Sold out 20 1,892,405

SEC 13F filings via Nasdaq, latest filings up to 30 Sep 2026. Filings arrive up to 45 days after each quarter.

Short Interest

Settlement Shares Days to cover
30 Oct 2026 29,318,686 13.2
15 Oct 2026 27,597,742 13.9
30 Sep 2026 28,748,212 13.1
15 Sep 2026 27,161,738 11.8
31 Aug 2026 25,478,782 7.2
14 Aug 2026 20,951,747 5.2

FINRA short interest via Nasdaq, reported twice a month.

2 Positive 1 Negative 8 Neutral
Date Type Details
18 Nov 2026 Yahoo Finance Aquestive Therapeutics to Present at the Piper Sandler 38th Annual Healthcare Conference
WARREN, N.J., Nov. 18, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a biopharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science, announced today that the management team will…
16 Nov 2026 Yahoo Finance Aquestive Therapeutics Eyes Needle-Free Allergy Treatment Launch Ahead of 2027 FDA Decision
Aquestive Therapeutics (NASDAQ:AQST) is preparing for a potential U.S. launch of its needle-free treatment for severe allergic reactions, with an FDA decision expected on March 16, 2027, CEO Dan Barber said at the 2026 Jefferies Global Healthcare Conference. The company’s lead product candidate, An…
09 Nov 2026 Yahoo Finance Aquestive Therapeutics to Present at the Jefferies Global Healthcare Conference
WARREN, N.J., Nov. 09, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a biopharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science, announced today that the management team will…
06 Nov 2026 Yahoo Finance Aquestive Therapeutics Inc (AQST) (Q3 2026) Earnings Call Highlights: Revenue Dip Masks Anifilm ...
Aquestive Therapeutics Inc (AQST) navigates quarterly revenue fluctuations while advancing Anifilm toward a March 2027 FDA decision and securing a $10 million upfront licensing deal for Libervant.
05 Nov 2026 Yahoo Finance Aquestive Therapeutics to Present Data at the 2026 ACAAI Annual Meeting
WARREN, N.J., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a biopharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science, today announced that multiple oral and poster…
04 Nov 2026 Yahoo Finance Aquestive Therapeutics, Inc. Q3 2026 Earnings Call Summary
Moby summary of Aquestive Therapeutics, Inc.'s Q3 2026 earnings call…
04 Nov 2026 Yahoo Finance Aquestive (AQST) Q3 2026 Earnings Call Transcript
Anaphylm's March 2027 FDA date anchors a launch push backed by new funding.
04 Nov 2026 Yahoo Finance What Aquestive Therapeutics (AQST) Said on Its Q3 Earnings Call
Aquestive Therapeutics (NASDAQ:AQST) said it resubmitted its application for Anaphylm, an epinephrine sublingual film intended for severe allergic reactions, before the end of the third quarter and is preparing for a potential U.S. launch next year if the product receives Food and Drug Administratio…
03 Nov 2026 Yahoo Finance Aquestive Therapeutics (AQST) Reports Q3 Loss, Misses Revenue Estimates
Aquestive Therapeutics (AQST) delivered earnings and revenue surprises of -30.00% and -31.51%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
03 Nov 2026 Yahoo Finance Aquestive Therapeutics: Q3 Earnings Snapshot
(AP) — Aquestive Therapeutics Inc. (AQST) on Tuesday reported a loss of $16…
03 Nov 2026 Yahoo Finance Aquestive Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update
Anaphylm resubmission accepted with PDUFA goal date of March 16, 2027 Anaphylm would be the first and only oral rescue medication for the treatment of severe allergic reactions, including anaphylaxis, if approvedCommercial preparations remain on track to support a potential U.S. launch of Anaphylm…
27 Oct 2026 Yahoo Finance Aquestive Therapeutics to Report Third Quarter 2026 Financial Results and Recent Business Highlights on November 3 and Host Conference Call on November 4 at 8:00 a.m. ET
WARREN, N.J., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a biopharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced that…
15 Oct 2026 Yahoo Finance Aquestive Therapeutics Announces FDA Acceptance of Anaphylm™ NDA Resubmission and PDUFA Goal Date of March 16, 2027
FDA accepted the resubmission as complete and classified it as a Class 2 responsePrescription Drug User Fee Act (PDUFA) goal action date set for March 16, 2027Ex-U.S. strategy remains on track with Canadian NDS planned for Q4 2026 WARREN, N.J., Oct. 15, 2026 (GLOBE NEWSWIRE) -- Aquestive…
14 Oct 2026 Yahoo Finance Eton Pharmaceuticals and Aquestive Therapeutics Announce Exclusive U.S. Licensing Agreement for LIBERVANT® (diazepam) Buccal Film
Differentiated, portable buccal film would offer patients and caregivers an alternative to existing nasal and rectal seizure rescue treatments, a market opportunity that exceeds $450 million annually in the U.S.Patient market research demonstrated strong preference for buccal film, with 71% of…
29 Sep 2026 Yahoo Finance Aquestive Therapeutics Strengthens Board of Directors with Appointment of Richard Daly
Appoints Rich Daly, a life sciences executive with more than 30 years of leadership experience across large pharmaceutical companies, emerging biotechnology companies, and public company boards, to its Board of Directors WARREN, N.J., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc.…
17 Sep 2026 Yahoo Finance Aquestive Therapeutics Announces Resubmission of New Drug Application to FDA for Anaphylm™ (dibutepinephrine) Sublingual Film
Resubmission supported by positive topline human factors and pharmacokinetic (PK) study results announced in August 2026FDA will determine the resubmission classification and establish the applicable review timeline following its initial review of the resubmission WARREN, N.J., Sept. 17, 2026…
07 Sep 2026 Yahoo Finance Aquestive Therapeutics (AQST): Second Chance At Anaphylm Comes Into Focus
On August 11, Aquestive Therapeutics (NASDAQ:AQST) reported second-quarter 2026 results and said it remains on track to resubmit its Anaphylm epinephrine film to the FDA in the third quarter of 2026. That single sentence carries the whole story here. A company living and dying by one product…
01 Sep 2026 Yahoo Finance Aquestive Therapeutics to Participate in Upcoming September Investor Conferences
WARREN, N.J., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, announced today that the…
Show more

Recent Signals candle patterns and EMA crosses

▼ Death cross 17 sessions ago · 28 Oct
Long term · EMA 50/200
The 50-day EMA crossed below the 200-day, a widely watched sign that the long-term trend has turned down.

Technical Setup Medium

Trend order
Slope
Entry
Volume
In a downtrend: the price is below its moving averages, and they are falling. It is close to them. Volume is heavier on down days.
Nearest support: 3.31 – 3.62 · strong level
Nearest resistance: 3.58 – 3.91 · strong level

AI Technical Analysis

Portfolio

AI Template

Your price alert

Risk Profile

| | | | |
Conservative
Moderate Conservative
Moderate
Moderate Aggressive
Aggressive
Margin of Safety (EP)
Partial Profit (TP1)
Target Profit (TP2)
Maximum Loss (SL)

Disclaimer: The above is for illustrative purposes only and is NOT investment advice. Seek advice from a qualified financial professional.

Entry Price (EP)

Take Profit 1 (TP1)

Take Profit 2 (TP2)

Stop Loss (SL)

Risk / Reward
TP1:
TP2:

Loss to SL against profit to each target, from EP. A ratio of 2 or more is usually sought.

52W Range
 
52WL
 
52WH
SL
EP
TP1
TP2

All alert prices are within 52 weeks price range

Realized Profit -
Unrealized Profit -
Dividend Received 2026 -
Total Profit -
Avg. Return -
Quantity (Buy) -
Avg. Price (Buy) -
Quantity (Sold) -
Avg. Price (Sold) -
No stocks matching your criteria